Influence of aeroallergen sensitization and nasal polyposis on mepolizumab response in eosinophilic severe asthma.

IF 2.6 3区 医学 Q2 ALLERGY
Fatma Arzu Akkus, Fatih Colkesen, Tugba Onalan, Recep Evcen, Mehmet Emin Gerek, Mehmet Kilinc, Filiz Sadi Aykan, Sevket Arslan
{"title":"Influence of aeroallergen sensitization and nasal polyposis on mepolizumab response in eosinophilic severe asthma.","authors":"Fatma Arzu Akkus, Fatih Colkesen, Tugba Onalan, Recep Evcen, Mehmet Emin Gerek, Mehmet Kilinc, Filiz Sadi Aykan, Sevket Arslan","doi":"10.2500/aap.2025.46.250003","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Studies on the impact of comorbidities on treatment responses in severe eosinophilic asthma (SEA) are limited. This study was a real-world investigation into how the presence or absence of nasal polyps (NP) and sensitivity to aeroallergens influence the outcomes of mepolizumab therapy. <b>Methods:</b> In this retrospective study, data obtained from patients with SEA and who received at least 6 months of mepolizumab treatment were analyzed. The patients were initially divided into two groups based on the presence of NPs. Within these two groups, the patients were further categorized into subgroups according to the presence of aeroallergen sensitivity (AE). Asthma-related outcomes in the resulting four groups were evaluated both before mepolizumab treatment and during the follow-up period. <b>Results:</b> Among the 36 patients with NPs, 14 (38.8%) had AE (NP+AE+), whereas 22 (61.2%) did not (NP+AE-). Of the 35 patients without NPs, 17 (48.5%) had AE (NP-AE+), and 18 (51.5%) did not (NP-AE-). The presence of NPs, independent of AE, was significantly associated with an increase in asthma exacerbations and oral corticosteroid (OCS) use before treatment (p < 0.001). In the NP+AE+ group, the baseline Asthma Control Test (ACT) score was lower, and the number of hospitalizations was significantly higher (p < 0.001). After mepolizumab treatment, all four groups showed significant reductions in asthma-related exacerbations, hospitalizations, and OCS use. Furthermore, ACT scores and pulmonary function test parameters significantly improved. There were limited differences in asthma improvements among the groups, with the NP+AE+ group showing a significant increase in ACT scores and a reduction in hospitalizations compared with the other groups (p < 0.001). <b>Conclusion:</b> Mepolizumab significantly reduced asthma exacerbations, hospitalizations, and OCS use in the patients with SEA with four different phenotypes. Analysis of these findings suggests that mepolizumab provides real-world benefits regardless of the presence or absence of NPs and AE.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"46 2","pages":"119-125"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy and asthma proceedings","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2500/aap.2025.46.250003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Studies on the impact of comorbidities on treatment responses in severe eosinophilic asthma (SEA) are limited. This study was a real-world investigation into how the presence or absence of nasal polyps (NP) and sensitivity to aeroallergens influence the outcomes of mepolizumab therapy. Methods: In this retrospective study, data obtained from patients with SEA and who received at least 6 months of mepolizumab treatment were analyzed. The patients were initially divided into two groups based on the presence of NPs. Within these two groups, the patients were further categorized into subgroups according to the presence of aeroallergen sensitivity (AE). Asthma-related outcomes in the resulting four groups were evaluated both before mepolizumab treatment and during the follow-up period. Results: Among the 36 patients with NPs, 14 (38.8%) had AE (NP+AE+), whereas 22 (61.2%) did not (NP+AE-). Of the 35 patients without NPs, 17 (48.5%) had AE (NP-AE+), and 18 (51.5%) did not (NP-AE-). The presence of NPs, independent of AE, was significantly associated with an increase in asthma exacerbations and oral corticosteroid (OCS) use before treatment (p < 0.001). In the NP+AE+ group, the baseline Asthma Control Test (ACT) score was lower, and the number of hospitalizations was significantly higher (p < 0.001). After mepolizumab treatment, all four groups showed significant reductions in asthma-related exacerbations, hospitalizations, and OCS use. Furthermore, ACT scores and pulmonary function test parameters significantly improved. There were limited differences in asthma improvements among the groups, with the NP+AE+ group showing a significant increase in ACT scores and a reduction in hospitalizations compared with the other groups (p < 0.001). Conclusion: Mepolizumab significantly reduced asthma exacerbations, hospitalizations, and OCS use in the patients with SEA with four different phenotypes. Analysis of these findings suggests that mepolizumab provides real-world benefits regardless of the presence or absence of NPs and AE.

嗜酸性严重哮喘患者气致过敏原致敏和鼻息肉病对美polizumab反应的影响。
背景:关于合并症对严重嗜酸性哮喘(SEA)治疗反应影响的研究有限。这项研究是一项真实世界的调查,探讨鼻息肉(NP)的存在或不存在以及对空气过敏原的敏感性如何影响美波珠单抗治疗的结果。方法:在这项回顾性研究中,对接受mepolizumab治疗至少6个月的SEA患者的数据进行分析。患者最初根据NPs的存在分为两组。在这两组患者中,根据是否存在空气过敏原敏感性(AE)进一步分为亚组。在mepolizumab治疗前和随访期间,对四组患者的哮喘相关结果进行评估。结果:36例NPs患者中,有AE (NP+AE+) 14例(38.8%),无AE (NP+AE-) 22例(61.2%)。35例无NPs患者中,17例(48.5%)发生AE (NP-AE+), 18例(51.5%)未发生AE (NP-AE-)。NPs的存在(独立于AE)与哮喘发作和治疗前口服皮质类固醇(OCS)使用的增加显著相关(p < 0.001)。NP+AE+组基线哮喘控制测试(ACT)评分较低,住院次数显著高于NP+AE+组(p < 0.001)。mepolizumab治疗后,所有四组均显示哮喘相关恶化、住院和OCS使用显著减少。此外,ACT评分和肺功能测试参数显著改善。两组之间哮喘改善的差异有限,与其他组相比,NP+AE+组的ACT评分显著增加,住院率显著降低(p < 0.001)。结论:Mepolizumab可显著降低四种不同表型SEA患者的哮喘加重、住院和OCS使用。对这些发现的分析表明,无论NPs和AE是否存在,mepolizumab都能提供实际的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
35.70%
发文量
106
审稿时长
6-12 weeks
期刊介绍: Allergy & Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists. The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma. Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信